Loading clinical trials...
Loading clinical trials...
Phase Ib Trial of ABBV-637 or ABBV-155 in Combination With ERAS-801 for Glioblastoma With Amplification of the Epidermal Growth Factor Receptor
Conditions
Interventions
ERAS-801
ABBV-637
+3 more
Locations
10
United States
University of Miami (Data collection only)
Miami, Florida, United States
Indiana University (Data Collection Only)
Indianapolis, Indiana, United States
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, United States
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
Commack, New York, United States
Start Date
April 7, 2025
Primary Completion Date
April 1, 2028
Completion Date
April 1, 2028
Last Updated
March 30, 2026
NCT05969860
NCT02800486
NCT05789394
NCT06860594
NCT05283330
NCT05839379
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions